Gene expression and biomarkers in renal transplant ischemia reperfusion injury

Transplant International

Volumn 20, Issue 1, 2007, Pages 2-11

  Perco, Paul ^a,b   Pleban, Clara ^b   Kainz, Alexander ^a   Lukas, Arno ^c   Mayer, Bernd ^b,c   Oberbauer, Rainer ^a  

^a ELISABETHINEN HOSPITAL   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Emergentec Biodevelopment GmbH   (Austria)

Author keywords

Acute renal failure; Biomarker; Gene expression; Inflammation; Kidney transplantation

Indexed keywords

BIOLOGICAL MARKER; GENE PRODUCT; PROTEIN;

ACUTE KIDNEY FAILURE; CADAVER DONOR; CADAVER KIDNEY; DISEASE MARKER; EXPERIMENTAL MODEL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENOME ANALYSIS; GRAFT RECIPIENT; HEALTH CARE MANAGEMENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 33845678148     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00376.x     Document Type: Review

References (65)

1. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889.
2. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
3. Canafax DM, Torres A, Fryd DS, et al. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine. Transplantation 1986; 41: 177.
4. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 1037.
5. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
6. Boom H, Mallat MJ, de Fijter JW, Zwinderman AH, Paul LC. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859.
7. Thongboonkerd V. Proteomics in nephrology: current status and future directions. Am J Nephrol 2004; 24: 360.
8. Thongboonkerd V. Proteomic analysis of renal diseases: unraveling the pathophysiology and biomarker discovery. Expert Rev Proteomics 2005; 2: 349.
9. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125.
10. Scherer A, Krause A, Walker JR, Korn A, Niese D, Raulf F. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 2003; 75: 1323.
11. Hauser P, Schwarz C, Mitterbauer C, et al. Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest 2004; 84: 353.
12. Melk A, Mansfield ES, Hsieh SC, et al. Transcriptional analysis of the molecular basis of human kidney aging using cDNA microarray profiling. Kidney Int 2005; 68: 2667.
13. Perco P, Blaha P, Kainz A, et al. Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl Int 2006; 19: 146.
14. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999; 21: 33.
15. Barczak A, Rodriguez MW, Hanspers K, et al. Spotted long oligonucleotide arrays for human gene expression analysis. Genome Res 2003; 13: 1775.
16. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat Genet 1999; 21: 20.
17. Perco P, Rapberger R, Siehs C, et al. Transforming omics data into context: Bioinformatics on genomics and proteomics raw data. Electrophoresis 2006; 27: 2653.
18. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004; 15: 1677.
19. Yoshida T, Kurella M, Beato F, et al. Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int 2002; 61: 1646.
20. Yoshida T, Tang SS, Hsiao LL, Jensen RV, Ingelfinger JR, Gullans SR. Global analysis of gene expression in renal ischemia-reperfusion in the mouse. Biochem Biophys Res Commun 2002; 291: 787.
21. Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003; 63: 1714.
22. Devarajan P, Mishra J, Supavekin S, Patterson LT, Potter SS. Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab 2003; 80: 365.
23. Kieran NE, Doran PP, Connolly SB, et al. Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int 2003; 64: 480.
24. Yuen PS, Jo SK, Holly MK, Hu X, Star RA. Ischemic and Nephrotoxic Acute Renal Failure are Distinguished by their Broad Transcriptomic Responses. Physiol Genomics 2006; 25: 375.
25. Schwarz C, Regele H, Steininger R, Hansmann C, Mayer G, Oberbauer R. The contribution of adhesion molecule expression in donor kidney biopsies to early allograft dysfunction. Transplantation 2001; 71: 1666.
26. Schwarz C, Hauser P, Steininger R, et al. Failure of BCL-2 up-regulation in proximal tubular epithelial cells of donor kidney biopsy specimens is associated with apoptosis and delayed graft function. Lab Invest 2002; 82: 941.
27. Kurian SM, Flechner SM, Kaouk J, et al. Laparoscopic donor nephrectomy gene expression profiling reveals upregulation of stress and ischemia associated genes compared to control kidneys. Transplantation 2005; 80: 1067.
28. Kainz A, Mitterbauer C, Hauser P, et al. Alterations in gene expression in cadaveric vs. live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. Am J Transplant 2004; 4: 1595.
29. Thomas PD, Kejariwal A, Campbell MJ, et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003; 31: 334.
30. Mi H, Lazareva-Ulitsky B, Loo R, et al. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res 2005; 33: D284.
31. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics 2005; 21: 2076.
32. Chen JY, Shen C, Sivachenko AY. Mining Alzheimer disease relevant proteins from integrated protein interactome data. Pac Symp Biocomput 2006; 11: 367.
33. Badid C, Desmouliere A, Babici D, et al. Interstitial expression of alpha-SMA: an early marker of chronic renal allograft dysfunction. Nephrol Dial Transplant 2002; 17: 1993.
34. Badid C, Desmouliere A, McGregor B, et al. Interstitial alpha-smooth muscle actin: a prognostic marker in membranous nephropathy. Clin Nephrol 1999; 52: 210.
35. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB, Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277: C1.
36. Zimmerhackl LB. Evaluation of nephrotoxicity with renal antigens in children: role of Tamm-Horsfall protein. Eur J Clin Pharmacol 1993; 44 (Suppl. 1): S39.
37. Lynn KL, Marshall RD. Excretion of Tamm-Horsfall glycoprotein in renal disease. Clin Nephrol 1984; 22: 253.
38. Scolari F, Caridi G, Rampoldi L, et al. Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 2004; 44: 987.
39. Nishiyama J, Kobayashi S, Ishida A, et al. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 2000; 157: 815.
40. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004; 19: 527.
41. Zahedi K, Wang Z, Barone S, et al. Expression of SSAT, a novel biomarker of tubular cell damage, increases in kidney ischemia-reperfusion injury. Am J Physiol Renal Physiol 2003; 284: F1046.
42. Barone S, Okaya T, Rudich S, et al. Distinct and sequential upregulation of genes regulating cell growth and cell cycle progression during hepatic ischemia-reperfusion injury. Am J Physiol Cell Physiol 2005; 289: C826.
43. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286: F552.
44. Hong ME, Hong JC, Stepkowski S, Kahan BD. Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene. Transplant Proc 2005; 37: 4254.
45. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290: 0F517.
46. Molls RR, Savransky V, Liu M, et al. Keratinocyte-derived chemokine is an early biomarker of ischemic acute kidney injury. Am J Physiol Renal Physiol 2005; 290: 0F1187.
47. Cheng CW, Rifai A, Ka SM, et al. Calcium-binding proteins annexin A2 and S100A6 are sensors of tubular injury and recovery in acute renal failure. Kidney Int 2005; 68: 2694.
48. Muramatsu Y, Tsujie M, Kohda Y, et al. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 2002; 62: 1601.
49. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003; 178: 169.
50. Pelinka LE, Harada N, Szalay L, Jafarmadar M, Redl H, Bahrami S. Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats. Shock 2004; 21: 72.
51. Pelinka LE, Toegel E, Mauritz W, Redl H. Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 2003; 19: 195.
52. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol 2005; 17: 167.
53. Herget-Rosenthal S, Poppen D, Husing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50: 552.
54. Flower DR. Beyond the superfamily: the lipocalin receptors. Biochim Biophys Acta 2000; 1482: 327.
55. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534.
56. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231.
57. Yang J, Mori K, Li JY, Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 2003; 285: 0F9.
58. Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J 2000; 14: 48.
59. Chatterjee PK, Todorovic Z, Sivarajah A, et al. Differential effects of caspase inhibitors on the renal dysfunction and injury caused by ischemia-reperfusion of the rat kidney. Eur J Pharmacol 2004; 503: 173.
60. Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. Faseb J 2001; 15: 2337.
61. Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004; 172: 3869.
62. Gueler F, Rong S, Park JK, et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002; 13: 2288.
63. Chatterjee SN, Terasaki PI, Fine S, Schulman B, Smith R, Fine RN. Pretreatment of cadaver donors with methylprednisolone in human renal allografts. Surg Gynecol Obstet 1977; 145: 729.
64. Jeffery JR, Downs A, Grahame JW, Lye C, Ramsey E, Thomson AE. A randomized prospective study of cadaver donor pretreatment in renal transplantation. Transplantation 1978; 25: 287.
65. Soulillou JP, Baron D, Rouxel A, Guenel J. Steroid-cyclophosphamide pretreatment of kidney allograft donors. A control study. Nephron 1979; 24: 193.